biliary tract cancer

97P Neoadjuvant D+GemCis vs gemcis alone for localized biliary tract cancer

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute and Post DM senior resident at AIIMS, New Delhi, shared on X:

”97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE) – Annals of Oncology”

Authors: C. Yoo, J.O. Park, K-P. Kim, J. Hyung, B-Y. Ryoo, J.Y. Hong, S.H. Shin, T.J. Song,  D. Oh, W. lee, B.J. Kwak, J.H. Lee, D.W. Hwang

97P Neoadjuvant D+GemCis vs gemcis alone for localized biliary tract cancer

Akhil Santhosh Annals of Oncology B-Y. Ryoo B.J. Kwak C. Yoo cancer D. Oh D.W. Hwang J. Hyung J.H. Lee J.O. Park J.Y. Hong K-P. Kim OncoDaily Oncology S.H. Shin T.J. Song W. lee